Insider Selling: Recursion Pharmaceuticals (NASDAQ:RXRX) CEO Sells 22,408 Shares of Stock

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) CEO Najat Khan sold 22,408 shares of the company’s stock in a transaction that occurred on Tuesday, September 8th. The stock was sold at an average price of $3.52, for a total transaction of $78,876.16. Following the completion of the sale, the chief executive officer directly owned 2,072,890 shares of the company’s stock, valued at approximately $7,296,572.80. This represents a 1.07% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Recursion Pharmaceuticals Price Performance

Shares of NASDAQ RXRX traded down $0.05 during mid-day trading on Thursday, reaching $3.16. 10,614,265 shares of the company traded hands, compared to its average volume of 18,001,195. Recursion Pharmaceuticals, Inc. has a fifty-two week low of $2.77 and a fifty-two week high of $7.18. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.03 and a quick ratio of 5.03. The firm has a market cap of $1.69 billion, a PE ratio of -3.04 and a beta of 1.07. The stock has a fifty day simple moving average of $3.32 and a 200-day simple moving average of $3.33.

Recursion Pharmaceuticals (NASDAQ:RXRX) last announced its earnings results on Wednesday, August 5th. The company reported ($0.25) EPS for the quarter, missing the consensus estimate of ($0.24) by ($0.01). The firm had revenue of $7.67 million for the quarter, compared to the consensus estimate of $10.97 million. Recursion Pharmaceuticals had a negative return on equity of 50.41% and a negative net margin of 945.94%.During the same period in the previous year, the firm earned ($0.41) EPS. Equities research analysts anticipate that Recursion Pharmaceuticals, Inc. will post -0.92 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of RXRX. MCF Advisors LLC acquired a new stake in shares of Recursion Pharmaceuticals during the 2nd quarter valued at $27,000. International Assets Investment Management LLC acquired a new position in shares of Recursion Pharmaceuticals in the 4th quarter worth $31,000. Sequoia Financial Advisors LLC acquired a new position in shares of Recursion Pharmaceuticals in the 4th quarter worth $41,000. NewEdge Advisors LLC raised its position in shares of Recursion Pharmaceuticals by 28.1% during the second quarter. NewEdge Advisors LLC now owns 11,061 shares of the company’s stock worth $56,000 after purchasing an additional 2,428 shares during the period. Finally, Fund Advisors of America Inc FL acquired a new stake in shares of Recursion Pharmaceuticals during the second quarter worth $45,000. Institutional investors own 89.06% of the company’s stock.

Analysts Set New Price Targets

RXRX has been the subject of several research analyst reports. Weiss Ratings restated a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a report on Friday, July 17th. Wall Street Zen upgraded shares of Recursion Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Saturday, August 29th. Finally, Morgan Stanley set a $5.30 price target on shares of Recursion Pharmaceuticals in a report on Monday, August 17th. Two research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $8.06.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc (NASDAQ: RXRX) is a biopharmaceutical company that combines advanced automation, artificial intelligence and high-throughput biology to discover and develop novel therapeutics. The company’s proprietary platform integrates deep-learning algorithms with large-scale cellular imaging and chemical biology, enabling the rapid identification of potential drug candidates across a range of indications. By automating complex laboratory workflows and leveraging computational models, Recursion aims to accelerate the drug discovery process and expand the scope of targets that can be addressed.

At the core of Recursion’s offering is its digital biology platform, which captures billions of cell images under varying chemical and genetic perturbations.